PYC Therapeutics (FRA:PH7) Cash-to-Debt : 46.70 (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is PYC Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. PYC Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 46.70.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, PYC Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for PYC Therapeutics's Cash-to-Debt or its related term are showing as below:

FRA:PH7' s Cash-to-Debt Range Over the Past 10 Years
Min: 25.53 Med: No Debt Max: No Debt
Current: 46.72

During the past 13 years, PYC Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 25.53. And the median was No Debt.

FRA:PH7's Cash-to-Debt is ranked better than
71.33% of 1486 companies
in the Biotechnology industry
Industry Median: 6.9 vs FRA:PH7: 46.72

PYC Therapeutics Cash-to-Debt Historical Data

The historical data trend for PYC Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

PYC Therapeutics Cash-to-Debt Chart

PYC Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

31.49

70.43

30.82

49.47

PYC Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															64.71	30.82	25.54	49.47	46.70

Competitive Comparison of PYC Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, PYC Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PYC Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PYC Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where PYC Therapeutics's Cash-to-Debt falls into.

PYC Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

PYC Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.646	/	(0.11	+	0.085)
	=	49.47

PYC Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	15.599	/	(0.199	+	0.135)
	=	46.70

PYC Therapeutics (FRA:PH7) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

PYC Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of PYC Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PYC Therapeutics (FRA:PH7) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PYC Therapeutics Ltd (FRA:PH7) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

PYC:Australia

Address

6 Verdun Street, Harry Perkins Institute of Medical Research, Nedlands, Perth, WA, AUS, 6009

Website

https://www.pyctx.com

PYC Therapeutics Ltd is an RNA therapeutics drug development company, leveraging a proprietary delivery platform to solve the challenges in RNA therapeutics - safe and effective delivery of the drug inside the cell. The company's principal business activity is of of drug development and progressing the company's drug pipeline through preclinical and clinical development. Geographically, it operates only in Australia.

PYC Therapeutics (FRA:PH7) Headlines

No Headlines